Skip to main content

Paradigm Genetics Posts Greater Revenue, Narrowed Loss in Q2

NEW YORK, Aug. 7 (GenomeWeb News) - Paradigm Genetics today reported a modest jump in second-quarter revenue atop declines in R&D spending a narrowed net loss.

 

Total revenue for the period ended June 30 increased to $5.6 million from $4.4 million year over year.

 

R&D spending dipped to $6.5 million from $7 million in the second-quarter 2002.

 

Consequently, net loss for the second quarter 2003 narrowed to $3.6 million, or $.11 per square, from $5 million, or $.16 per share, in the same period last year.

 

Paradigm said it had around 9.3 million in cash, cash equivalents and short-term investments as of June 30.

 

Click here for more information.

 

Last month, Paradigm pocketed $7.5 million as part of a  debt-financing deal with Silicon Valley Bank of Santa Clara, Calif. Paradigm said the financing includes a $5 million, four-year secured-term loan and a $2.5 million revolving line of credit. The firm added that the loan is at a "significantly lower [interest] rate" than its existing loan.

 

Paradigm, based in Research Triangle Park, NC, will use around $3 million of the term loan to pay off its current equipment financing loan with Transamerica Technology Finance, which was to mature in June 2004. The company said it will use the balance of the cash for "general corporate purposes."

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.